Brief: Cidara Therapeutics Receives Barda Award Valued Up To $339 Million
02/10/2025 21:21
Oct 2 (Reuters) - Cidara Therapeutics Inc CDTX.O: CIDARA THERAPEUTICS ANNOUNCES BARDA AWARD TO SUPPORT EXPANDED MANUFACTURING AND CLINICAL DEVELOPMENT OF CD388, ITS NON-VACCINE INFLUENZA PREVENTATIVE THERAPEUTIC CIDARA THERAPEUTICS INC - RECEIVES BARDA AWARD VALUED UP TO $339 MILLION CIDARA THERAPEUTICS INC - BASE PERIOD FUNDING OF $58 MILLION OVER 24 MONTHS SUPPORTS CD388 MANUFACTURING IN U.S. Source text: ID:nGNX7H80tw Further company coverage: CDTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cidara Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merck Seeks Up To $8 Billion In Us Bond Sale Tied To Cidara Deal - Bloomberg News
Merck rises after Wells Fargo upgrades stock to 'overweight'
Factbox: Major deals involving U.S. drugmakers and biotechs over the past decade